What is Vosoritide: Uses, Dosage, Side Effects and More

Vosoritide is a breakthrough medication specifically designed to help children with achondroplasia grow taller. This daily injection represents the first FDA-approved treatment that can actually increase growth velocity in kids with the most common form of dwarfism.

If your child has been diagnosed with achondroplasia, you might feel overwhelmed by treatment options. Vosoritide offers new hope by working directly with your child's growth processes, though like any medication, it comes with important considerations we'll explore together.

What is Vosoritide?

Vosoritide is a synthetic version of a natural protein called C-type natriuretic peptide (CNP). Think of CNP as your body's own growth helper that gets blocked in children with achondroplasia.

The medication works by mimicking this natural protein, helping to restore some of the normal growth processes that achondroplasia interferes with. It's given as a small injection under the skin once daily, similar to how some people with diabetes take insulin.

This isn't a cure for achondroplasia, but it can help children grow closer to their potential height. The medication has been extensively studied and represents years of research into understanding how growth works in children with this condition.

What is Vosoritide Used For?

Vosoritide is specifically approved to increase linear growth in children with achondroplasia who are at least 2 years old. Linear growth refers to getting taller, which is often the primary concern for families dealing with this condition.

Your doctor might recommend vosoritide if your child has confirmed achondroplasia through genetic testing and is still growing. The medication works best when started during active growth periods, typically in childhood and adolescence.

It's important to understand that vosoritide only helps with height growth. It doesn't address other aspects of achondroplasia like limb proportions, joint issues, or breathing problems that some children experience.

How Does Vosoritide Work?

Vosoritide works by targeting the specific problem that causes short stature in achondroplasia. In this condition, a protein called FGFR3 sends too many "stop growing" signals to the growth plates in bones.

The medication acts like a helpful messenger that counteracts these negative signals. It binds to receptors in the growth plates and tells them to keep growing, even when FGFR3 is trying to slow things down.

This is considered a targeted therapy, meaning it works specifically on the biological pathway that's disrupted in achondroplasia. While it's not an extremely powerful medication, it provides consistent, measurable improvements in growth velocity for most children who take it.

How Should I Take Vosoritide?

Vosoritide is given as a subcutaneous injection, which means it goes into the fatty tissue just under the skin. Your healthcare team will teach you and your child how to give these injections safely at home.

The injection should be given once daily, preferably at the same time each day to maintain consistent levels in your child's system. Most families find that incorporating it into their bedtime or morning routine works well.

You can give the injection in several areas including the thighs, upper arms, or abdomen. It's important to rotate injection sites to prevent skin irritation. The medication doesn't need to be taken with food, but keeping it refrigerated until use is essential.

Your child's doctor will determine the exact dose based on their weight. The medication comes in pre-filled syringes, making it easier to ensure accurate dosing every time.

How Long Should I Take Vosoritide For?

Vosoritide is typically continued as long as your child is still growing and benefiting from the treatment. Most children take it throughout their growth years, which can extend into late adolescence.

Your doctor will monitor your child's growth regularly through measurements and X-rays to see how well the medication is working. Growth velocity usually improves within the first few months of treatment, with continued benefits over time.

The decision to stop vosoritide usually happens when your child's growth plates close, which typically occurs in late puberty. Some families also choose to discontinue if side effects become problematic or if the child decides they no longer want to continue injections.

What Are the Side Effects of Vosoritide?

Like all medications, vosoritide can cause side effects, though many children tolerate it well. Understanding what to expect can help you feel more prepared and confident about the treatment.

The most common side effects are generally mild and tend to improve as your child's body adjusts to the medication:

• Injection site reactions like redness, swelling, or mild pain
• Nausea or stomach upset
• Decreased blood pressure, which might cause dizziness
• Vomiting, especially during the first few weeks
• Fatigue or feeling more tired than usual

Most of these side effects are temporary and manageable. Your healthcare team can provide strategies to minimize discomfort and help your child adjust to the treatment.

More serious side effects are less common but important to watch for. These might include severe allergic reactions, persistent low blood pressure, or unusual changes in your child's overall health.

If you notice any concerning symptoms, especially difficulty breathing, severe dizziness, or signs of an allergic reaction, contact your healthcare provider immediately. Regular check-ups will help monitor for any potential issues.

Who Should Not Take Vosoritide?

Vosoritide isn't appropriate for everyone, and your doctor will carefully evaluate whether it's right for your child. Certain medical conditions or circumstances might make this treatment unsuitable.

Children who should not take vosoritide include those with severe kidney disease, as the medication is processed through the kidneys. Kids with certain heart conditions or severe low blood pressure may also need to avoid this treatment.

Your doctor will also consider your child's overall health, other medications they're taking, and any history of allergic reactions. Very young children under 2 years old are not approved for this treatment, as safety and effectiveness haven't been established in this age group.

If your child has closed growth plates, vosoritide won't be beneficial since there's no longer potential for height growth. Your doctor can determine growth plate status through X-rays if needed.

Vosoritide Brand Name

Vosoritide is marketed under the brand name Voxzogo in the United States. This is the only brand name currently available, as it's a newer medication with patent protection.

Voxzogo is manufactured by BioMarin Pharmaceutical and is the same medication whether referred to by its generic name (vosoritide) or brand name. Currently, there are no generic versions available.

When discussing this medication with your healthcare team or insurance company, they may use either name interchangeably. It's helpful to know both names when advocating for coverage or asking questions about the treatment.

Vosoritide Alternatives

Currently, vosoritide is the only FDA-approved medication specifically designed to increase growth in children with achondroplasia. This makes it unique in the treatment landscape for this condition.

Before vosoritide became available, growth hormone therapy was sometimes tried, but it showed limited effectiveness for children with achondroplasia. Growth hormone works differently and doesn't address the specific growth pathway problems in this condition.

Other management approaches focus on addressing complications rather than height growth. These might include physical therapy, orthopedic interventions for bone and joint issues, or surgical procedures for specific problems like spinal stenosis.

Some families also consider limb lengthening surgery, though this is a much more intensive process with different risks and benefits. Your healthcare team can help you understand all available options for your child's specific situation.

Is Vosoritide Better Than Growth Hormone?

For children with achondroplasia, vosoritide has shown much more promising results than traditional growth hormone therapy. Growth hormone was tried in the past but showed minimal effectiveness for this specific condition.

The key difference is that vosoritide targets the exact biological problem causing short stature in achondroplasia, while growth hormone works through different pathways that aren't as effective when FGFR3 is overactive.

Clinical studies have demonstrated that vosoritide can increase growth velocity by an average of 1.5 to 2 centimeters per year compared to untreated children. Growth hormone therapy didn't show this level of consistent improvement in achondroplasia patients.

However, every child is different, and your doctor will consider your child's specific circumstances, growth patterns, and overall health when recommending the best treatment approach.